Celgene has recruited an R&D executive as part of an organisational shake - up designed to tackle issues with its drug portfolio . Alise ##k , MD , who worked with Merck on immuno - resistant drug Keytruda , has been brought in to lead mid- to late - stage drug development across Celgene ’s portfolio . The appointment follows an audit in May which revealed that two - thirds of the firm ’s drug programmes had failed over the past five years , with only one in ##patient satisfaction resulting in a marketed product .
Celgene has recruited an R&D executive as part of an organisational shake-up designed to tackle issues with its drug pipeline. Alise Reicin, MD, who worked with Merck on immuno-oncology drug Keytruda, has been brought in to lead mid- to late-stage drug development across Celgene’s portfolio. The appointment follows an audit in May which revealed that two-thirds of the firm’s R&D programmes had failed over the past five years, with only one in 20 programmes resulting in a marketed product.